Truist Financial’s Minerva Neurosciences NERV Stock Holding History

Truist Financial’s Portfolio NERV Stock Details NERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-11,043	Closed	-$102K	–	2648
2022 Q3	$102K	Buy	+11,043	New	+$65.4K	﹤0.01%	2418

Other funds holding NERV

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Truist Financial's NERV Position: Q4 2022 in Review

Truist Financial sold out of Minerva Neurosciences (NERV) in Q4 2022, closing a stake of 11,043 shares — an estimated $102K sold.

Truist Financial first reported a position in NERV in Q3 2022 and held it in 1 quarter. The position peaked at $102K in Q3 2022. 19 funds tracked by Wall St. Rank hold NERV as of Q4 2022.

Truist Financial reported no remaining Minerva Neurosciences position as of Q4 2022 after selling out during the quarter.
Truist Financial sold 11,043 Minerva Neurosciences shares in Q4 2022, an estimated $102K.
Truist Financial first reported a position in Minerva Neurosciences in Q3 2022 and held it in 1 quarter.
Truist Financial's Minerva Neurosciences position peaked at $102K in Q3 2022.
19 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q4 2022.

Based on Truist Financial's 13F filing for Q4 2022, filed 17 Feb 2023.